Controversies in Lymphoma: The Role of Hematopoietic Cell Transplantation for Mantle Cell Lymphoma and Peripheral T Cell Lymphoma

Biology of Blood and Marrow Transplantation

Volumn 14, Issue 1 SUPPL., 2008, Pages 100-107

  Dreger, Peter ^a   Laport, Ginna G ^b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Allogeneic; Autologous; Hematopoietic cell transplantation; Mantle cell lymphoma; Peripheral T cell lymphoma

Indexed keywords

ALEMTUZUMAB; ANTINEOPLASTIC AGENT; BORTEZOMIB; BUSULFAN; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; EVEROLIMUS; FLUDARABINE; IBRITUMOMAB TIUXETAN; IMMUNOSUPPRESSIVE AGENT; INTERFERON; LACTATE DEHYDROGENASE; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MELPHALAN; METHOTREXATE; MITOXANTRONE; MONOCLONAL ANTIBODY; PREDNISONE; PROTEIN BCL 2 INHIBITOR; RITUXIMAB; TEMSIROLIMUS; THIOPENTAL; TOSITUMOMAB I 131; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINCRISTINE;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BONE MARROW PURGING; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; DISEASE COURSE; DISEASE FREE SURVIVAL; DRUG DOSE ESCALATION; DRUG DOSE SEQUENCE; DRUG EFFICACY; DRUG FATALITY; DRUG MEGADOSE; DRUG SAFETY; FOLLOW UP; GRAFT VERSUS HOST REACTION; HISTOPATHOLOGY; HUMAN; MAINTENANCE THERAPY; MANTLE CELL LYMPHOMA; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MYELOABLATIVE CONDITIONING; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PERIPHERAL T CELL LYMPHOMA; PROGNOSIS; PROSPECTIVE STUDY; REDUCED INTENSITY CONDITIONING; STEM CELL MOBILIZATION; SURVIVAL RATE; SURVIVAL TIME;

ANTINEOPLASTIC AGENTS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOMA, MANTLE-CELL; LYMPHOMA, T-CELL, PERIPHERAL; TRANSPLANTATION CONDITIONING;

EID: 37349000981     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2007.10.019     Document Type: Article

References (59)

1. Meusers P., Engelhard M., Bartels H., et al. Multicentre randomized therapeutic trial for advanced centrocytic lymphoma: anthracycline does not improve the prognosis. Hematol Oncol 7 (1989) 365-380
2. Lenz G., Dreyling M., Hoster E., et al. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol 23 (2005) 1984-1992
3. Weisenburger D.D., and Armitage J.O. Mantle cell lymphoma-an entity comes of age. Blood 87 (1996) 4483-4494
4. Stewart D.A., Vose J.M., Weisenburger D.D., et al. The role of high-dose therapy and autologous hematopoietic stem cell transplantation for mantle cell lymphoma. Ann Oncol 6 (1995) 263-266
5. Freedman A.S., Neuberg D., Gribben J.G., et al. High-dose chemoradiotherapy and anti-B-cell monoclonal antibody-purged autologous bone marrow transplantation in mantle-cell lymphoma: no evidence for long-term remission. J Clin Oncol 16 (1998) 13-18
6. Dreger P., Martin S., Kuse R., et al. The impact of autologous stem cell transplantation on the prognosis of mantle cell lymphoma: a joint analysis of two prospective studies with 46 patients. Hematol J 1 (2000) 87-94
7. Vandenberghe E., Ruiz de Elvira C., Loberiza F.R., et al. Outcome of autologous transplantation for mantle cell lymphoma: a study by the European Blood and Bone Marrow Transplant and Autologous Blood and Marrow Transplant Registries. Br J Haematol 120 (2003) 793-800
8. Dreyling M., Lenz G., Hoster E., et al. Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. Blood 105 (2005) 2677-2684
9. Howard O.M., Gribben J.G., Neuberg D.S., et al. Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival. J Clin Oncol 20 (2002) 1288-1294
10. Delarue R., Haioun C., Brice P., et al. CHOP and DHAP plus rituximab followed by autologous stem cell transplantation (ASCT) in mantle cell lymphoma (MCL): a pilot study from the GELA. J Clin Oncol 22 (2004) 6529
11. Khouri I.F., Saliba R.M., Okoroji G.J., et al. Long-term follow-up of autologous stem cell transplantation in patients with diffuse mantle cell lymphoma in first disease remission: the prognostic value of beta2-microglobulin and the tumor score. Cancer 98 (2003) 2630-2635
12. Lefrere F., Delmer A., Levy V., et al. Sequential chemotherapy regimens followed by high-dose therapy with stem cell transplantation in mantle cell lymphoma: an update of a prospective study. Haematologica 89 (2004) 1275-1276
13. Pott C., Schrader C., Gesk S., et al. Quantitative assessment of molecular remission after high-dose therapy with autologous stem cell transplantation predicts long-term remission in mantle cell lymphoma. Blood 107 (2006) 2271-2278
14. Romaguera J.E., Fayad L., Rodriguez M.A., et al. High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol 23 (2005) 7013-7023
15. Mangel J., Leitch H.A., Connors J.M., et al. Intensive chemotherapy and autologous stem-cell transplantation plus rituximab is superior to conventional chemotherapy for newly diagnosed advanced stage mantle-cell lymphoma: a matched pair analysis. Ann Oncol 15 (2004) 283-290
16. Brugger W., Hirsch J., Grunebach F., et al. Rituximab consolidation after high-dose chemotherapy and autologous blood stem cell transplantation in follicular and mantle cell lymphoma: a prospective, multicenter phase II study. Ann Oncol 15 (2004) 1691-1698
17. Gianni A.M., Magni M., Martelli M., et al. Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen). Blood 102 (2003) 749-755
18. de Guibert S., Jaccard A., Bernard M., et al. Rituximab and DHAP followed by intensive therapy with autologous stem-cell transplantation as first-line therapy for mantle cell lymphoma. Haematologica 91 (2006) 425-426
19. Geisler C.H., Elonen E., Kolstad A., et al. Nodic Mantle Cell Lymphoma (MCL) Project: prolonged follow-up of 86 patients treated with BEAM/BEAC + PBSCT confirms that addition of high-dose ara-C and rituximab to CHOP induction + in-vivo purging with rituximab increases clinical and molecular response rates, PCR-neg. grafts, failure-free, relapse-free and overall survival. Blood 104 (2004) 6a
20. Dreger P., Rieger M., Seyfarth B., et al. Rituximab-augmented myeloablation for first-line autologous stem cell transplantation for mantle cell lymphoma: effects on molecular response and clinical outcome. Haematologica 92 (2007) 42-49
21. Khouri I.F., Lee M.S., Romaguera J., et al. Allogeneic hematopoietic transplantation for mantle-cell lymphoma: molecular remissions and evidence of graft-versus-malignancy. Ann Oncol 10 (1999) 1293-1299
22. Maris M.B., Sandmaier B.M., Storer B.E., et al. Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma. Blood 104 (2004) 3535-3542
23. Khouri I.F., Lee M.S., Saliba R.M., et al. Nonablative allogeneic stem-cell transplantation for advanced/recurrent mantle-cell lymphoma. J Clin Oncol 21 (2003) 4407-4412
24. Gopal A.K., Rajendran J.G., Petersdorf S.H., et al. High-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma. Blood 99 (2002) 3158-3162
25. Nademanee A., Forman S., Molina A., et al. A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma. Blood 106 (2005) 2896-2902
26. Belch A., Kouroukis C.T., Crump M., et al. A phase II study of bortezomib in mantle cell lymphoma: the National Cancer Institute of Canada Clinical Trials Group trial IND.150. Ann Oncol 18 (2007) 116-121
27. Fisher R.I., Bernstein S.H., Kahl B.S., et al. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol 24 (2006) 4867-4874
28. Weigert O., Pastore A., Rieken M., et al. Sequence-dependent synergy of the proteasome inhibitor bortezomib and cytarabine in mantle cell lymphoma. Leukemia 21 (2007) 524-528
29. Witzig T.E., Geyer S.M., Ghobrial I., et al. Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J Clin Oncol 23 (2005) 5347-5356
30. Haritunians T., Mori A., O'Kelly J., et al. Antiproliferative activity of RAD001 (everolimus) as a single agent and combined with other agents in mantle cell lymphoma. Leukemia 21 (2007) 333-339
31. Perez-Galan P., Roue G., Villamor N., et al. The BH3-mimetic GX15-070 synergizes with bortezomib in mantle cell lymphoma by enhancing Noxa-mediated activation of Bak. Blood 109 (2007) 4441-4449
32. Savage K.J. Aggressive peripheral T-cell lymphomas (specified and unspecified types). Hematology Am Soc Hematol Educ Program (2005) 267-277
33. Zinzani P.L., Bendandi M., Martelli M., et al. Anaplastic large-cell lymphoma: clinical and prognostic evaluation of 90 adult patients. J Clin Oncol 14 (1996) 955-962
34. Escalon M.P., Liu N.S., Yang Y., et al. Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma: the M. D. Anderson Cancer Center experience. Cancer 103 (2005) 2091-2098
35. Rodriguez J., Conde E., Gutierrez A., et al. The adjusted International Prognostic Index and beta-2-microglobulin predict the outcome after autologous stem cell transplantation in relapsing/refractory peripheral T-cell lymphoma. Haematologica 92 (2007) 1067-1074
36. Rodriguez J., Caballero M.D., Gutierrez A., et al. High-dose chemotherapy and autologous stem cell transplantation in peripheral T-cell lymphoma: the GEL-TAMO experience. Ann Oncol 14 (2003) 1768-1775
37. Feyler S., Prince H.M., Pearce R., et al. The role of high-dose therapy and stem cell rescue in the management of T-cell malignant lymphomas: a BSBMT and ABMTRR study. Bone Marrow Transplant 40 (2007) 443-450
38. Kewalramani T., Zelenetz A.D., Teruya-Feldstein J., et al. Autologous transplantation for relapsed or primary refractory peripheral T-cell lymphoma. Br J Haematol 134 (2006) 202-207
39. Rodriguez J., Caballero M.D., Gutierrez A., et al. High dose chemotherapy and autologous stem cell transplantation in patients with peripheral T-cell lymphoma not achieving complete response after induction chemotherapy. The GEL-TAMO experience. Haematologica 88 (2003) 1372-1377
40. Blystad A.K., Enblad G., Kvaloy S., et al. High-dose therapy with autologous stem cell transplantation in patients with peripheral T cell lymphomas. Bone Marrow Transplant 27 (2001) 711-716
41. Fanin R., Ruiz de Elvira M.C., Sperotto A., et al. Autologous stem cell transplantation for T and null cell CD30-positive anaplastic large cell lymphoma: analysis of 64 adult and paediatric cases reported to the European Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant 23 (1999) 437-442
42. Jagasia M., Morgan D., Goodman S., et al. Histology impacts the outcome of peripheral T-cell lymphomas after high dose chemotherapy and stem cell transplant. Leuk Lymphoma 45 (2004) 2261-2267
43. Smith S.D., Bolwell B.J., Rybicki L.A., et al. Autologous hematopoietic stem cell transplantation in peripheral T-cell lymphoma using a uniform high-dose regimen. Bone Marrow Transplant 40 (2007) 239-243
44. Pautier P., Devidas A., Delmer A., et al. Angioimmunoblastic-like T-cell non Hodgkin's lymphoma: outcome after chemotherapy in 33 patients and review of the literature. Leuk Lymphoma 32 (1999) 545-552
45. Rodriguez J., Conde E., Gutierrez A., et al. Prolonged survival of patients with angioimmunoblastic T-cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation: the GELTAMO experience. Eur J Haematol 78 (2007) 290-296
46. Schetelig J., Fetscher S., Reichle A., et al. Long-term disease-free survival in patients with angioimmunoblastic T-cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation. Haematologica 88 (2003) 1272-1278
47. Reimer P., Schertlin T., Rudiger T., et al. Myeloablative radiochemotherapy followed by autologous peripheral blood stem cell transplantation as first-line therapy in peripheral T-cell lymphomas: first results of a prospective multicenter study. Hematol J 5 (2004) 304-311
48. Corradini P., Tarella C., Zallio F., et al. Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation. Leukemia 20 (2006) 1533-1538
49. Rodriguez J., Conde E., Gutierrez A., et al. Frontline autologous stem cell transplantation in high-risk peripheral T-cell lymphoma: a prospective study from The Gel-Tamo Study Group. Eur J Haematol 79 (2007) 32-38
50. Murashige N., Kami M., Kishi Y., et al. Allogeneic haematopoietic stem cell transplantation as a promising treatment for natural killer-cell neoplasms. Br J Haematol 130 (2005) 561-567
51. Corradini P., Dodero A., Zallio F., et al. Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin's lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells. J Clin Oncol 22 (2004) 2172-2176
52. Laudi N., Arora M., Burns L., et al. Efficacy of high-dose therapy and hematopoietic stem cell transplantation for mantle cell lymphoma. Am J Hematol 81 (2006) 519-524
53. Ganti A.K., Bierman P.J., Lynch J.C., et al. Hematopoietic stem cell transplantation in mantle cell lymphoma. Ann Oncol 16 (2005) 618-624
54. Robinson S.P., Goldstone A.H., Mackinnon S., et al. Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation. Blood 100 (2002) 4310-4316
55. Morris E., Thomson K., Craddock C., et al. Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma. Blood 104 (2004) 3865-3871
56. Kim M.K., Kim S., Lee S.S., et al. High-dose chemotherapy and autologous stem cell transplantation for peripheral T-cell lymphoma: complete response at transplant predicts survival. Ann Hematol 86 (2007) 435-442
57. Song K.W., Mollee P., Keating A., et al. Autologous stem cell transplant for relapsed and refractory peripheral T-cell lymphoma: variable outcome according to pathological subtype. Br J Haematol 120 (2003) 978-985
58. Rodriguez J., Conde E., Gutierrez A., et al. The results of consolidation with autologous stem-cell transplantation in patients with peripheral T-cell lymphoma (PTCL) in first complete remission: the Spanish Lymphoma and Autologous Transplantation Group experience. Ann Oncol 18 (2007) 652-657
59. Mounier N., Gisselbrecht C., Briere J., et al. Prognostic factors in patients with aggressive non-Hodgkin's lymphoma treated by front-line autotransplantation after complete remission: a cohort study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 22 (2004) 2826-2834